Clearstead Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
Other funds holding CPRX
GCL
HI
Clearstead Advisors's CPRX Position: Q2 2026 in Review
Clearstead Advisors opened a new position in Catalyst Pharmaceutical (CPRX) in Q2 2026: 154 shares worth $4.84K. The stake represents ﹤0.01% of the portfolio and ranks #2206 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in CPRX as recently as Q4 2025.
Clearstead Advisors first reported a position in CPRX in Q2 2025 and has held it in 4 quarters since. The position peaked at $41.4K in Q4 2025. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.
- Clearstead Advisors held 154 shares of Catalyst Pharmaceutical worth $4.84K as of Q2 2026.
- Catalyst Pharmaceutical was a new Clearstead Advisors position in Q2 2026.
- Catalyst Pharmaceutical made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #2206 holding.
- Clearstead Advisors first reported a position in Catalyst Pharmaceutical in Q2 2025 and has held it in 4 quarters since.
- Clearstead Advisors's Catalyst Pharmaceutical position peaked at $41.4K in Q4 2025.
- 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.
Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.